Holen Sie sich die Stockscreener-App
15.46
11.71%
1.62
Handel nachbörslich:
14.68
-0.78
-5.05%
Schlusskurs vom Vortag:
$13.84
Offen:
$14.15
24-Stunden-Volumen:
964.78K
Relative Volume:
1.12
Marktkapitalisierung:
$950.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-219.88M
KGV:
-4.1517
EPS:
-3.7238
Netto-Cashflow:
$-175.76M
1W Leistung:
+9.07%
1M Leistung:
+16.94%
6M Leistung:
+31.69%
1J Leistung:
+97.95%
1-Tages-Spanne:
$14.00
$15.52
1-Wochen-Bereich:
$13.70
$15.52
52-Wochen-Spanne:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
15.46 | 850.58M | 0 | -219.88M | -175.76M | -3.7238 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (CGEM) Plans Immunology Day Event in NYC - GuruFocus
Cullinan Therapeutics to Host Immunology Day to Showcase - GlobeNewswire
Wedbush maintains Cullinan Therapeutics (CGEM) outperform recommendation - MSN
Cullinan Therapeutics, Inc. $CGEM Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
CGEM Technical Analysis | Trend, Signals & Chart Patterns | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail
CGEM Reiterated by BTIG -- Price Target Maintained at $38 - GuruFocus
FDA grants orphan drug status to Cullinan’s CLN-049 for AML - Investing.com Nigeria
Cullinan Therapeutics (CGEM) Gets Buy Rating Boost with $33 Targ - GuruFocus
Stifel reiterates Cullinan Oncology stock rating on trial data - Investing.com India
FDA grants orphan drug status to Cullinan’s CLN-049 for AML By Investing.com - Investing.com South Africa
Stifel reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
CGEM Secures Orphan Drug Designation for CLN-049 in AML Treatmen - GuruFocus
BTIG Research Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics Receives FDA Orphan Drug Designation - GlobeNewswire
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell ... - Caledonian Record
Cullinan Therapeutics Presents Promising Phase 1 Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 1 - Minichart
Cullinan Therapeutics to present initial clinical data for CLN-978 in RA and SLE at EULAR 2026 - Pluang
cullinan therapeutics, inc. Earnings dates - RTTNews
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data - TipRanks
Cullinan Therapeutics to present Phase 1 CLN-978 data showing robust B‑cell depletion, favorable safety at EULAR - TradingView
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress - The Manila Times
Cullinan Therapeutics to Present Initial Clinical Data for - GlobeNewswire
Alzheimer's and cancer: 10 trial drugs trace back to one antibody lab - Stock Titan
[SCHEDULE 13G/A] Cullinan Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Cullinan Therapeutics, Inc.Common Stock (Nasdaq:CGEM) Stock Quote - FinancialContent
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
UBS Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $24 - Moomoo
HC Wainwright Issues Positive Forecast for CGEM Earnings - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Wall Street Zen Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Hold - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Issues Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
CGEM Maintained by Wedbush -- Price Target Raised to $37.00 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $37.00 - MarketBeat
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Raises Target Price to $37 - Moomoo
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: A Biotech Contender with 114% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - Investing News Network
Cullinan Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (CGEM) Cullinan Therapeutics, Inc. Reports Q1 Loss of $0.75 - Moomoo
Cullinan Therapeutics: Q1 Earnings Snapshot - Barchart.com
Cullinan Therapeutics 1Q 2026: Revenue $0 EPS $(0.75) — 10-Q Summary - TradingView
Cullinan Therapeutics unveils key financial results and outlines upcoming development milestones - Traders Union
Cullinan Therapeutics (CGEM) logs Q1 loss as FDA accepts zipalertinib NDA and cash tops $351.9M - Stock Titan
Cullinan Therapeutics Q1 net loss widens - TradingView
Cullinan Therapeutics (CGEM) posts Q1 loss, advances autoimmune and cancer pipeline - Stock Titan
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):